Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME study in metastatic hormone-sensitive prostate cancer
jRCTs031250343Recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of enzalutamide in prostate cancer (PCa) (4 arms), sponsored by Astellas Pharma. Primary endpoint: Proportion of patients achieving PSA <= 0.2 ng/mL within 2 years after initiation of enzalutamide. Started Sep 2025; status: recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs031250343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250343.